Skip to main content

Table 2 Incidence of cardiac or vascular-related adverse events

From: Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring

Adverse event of interest

Patients reporting grade ≥3 adverse event,n

Patients reporting grade≥3 adverse event with history of the adverse event,n

Hypertension

5

4

Congestive heart failure

5

3

Pulmonary hypertension

2

2

Lung disease

1

0

Renal failure

6

6